
Mantle Cell Lymphoma
Latest News


FDA Grants Breakthrough Therapy Designation to Sonrotoclax for R/R Mantle Cell Lymphoma
Latest Videos

CME Content
More News

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Ruby Arora, MD, discusses the declining incidence of MCL in the US, as well as ways to address disparities that remain in MCL management.

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Ruby Arora, MD, discusses a study investigating survival outcomes and sociodemographic disparities among patients with MCL from 2000 to 2021.

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Mats Jerkeman, MD, discusses the importance of conducting further research to classify the biological heterogeneity within MCL.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Ruby Arora, MD, discusses an analysis of SEER data on the declining MCL incidence and disparities that persist in Hispanic and American Indian patients.

Mats Jerkeman, MD, discusses the use of induction chemoimmunotherapy followed by high-dose chemotherapy and ASCT in younger patients with MCL.

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

Martin Dreyling, MD, PhD, discusses clinical trial findings with acalabrutinib plus BR in patients with high-risk mantle cell lymphoma.

The FDA granted regenerative medicine advanced therapy designation to GLPG5101 for relapsed/refractory mantle cell lymphoma.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

The combination of sonrotoclax and zanubrutinib produced deep and durable responses in relapsed/refractory mantle cell lymphoma.

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.


















































